Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986527 in Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07848295Phase 1Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2026
- Primary completion
- Oct 2030
- Countries
- 7
01
Overview
Phase 1, open-label trial of BMS-986527 in clear cell renal cell carcinoma (ccRCC) (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events up to 2 years, Incidence of serious adverse events up to 2 years and 3 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BMS-986527
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07848295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07848295.